Last updated: August 6, 2026
Carvedilol phosphate is the extended-release formulation marketed in the United States as Coreg CR. Its commercial value has declined from branded cardiovascular franchise levels to a smaller, mature generic market. The formulation retains clinical differentiation through once-daily dosing, but its market position is constrained by low-cost immediate-release carvedilol, generic metoprolol succinate, and other beta-blockers.
Standalone revenue for carvedilol phosphate is not separately disclosed in public financial reports. GSK reports carvedilol within broader product or cardiovascular categories, while generic manufacturers generally do not report product-level revenue. The most reliable commercial conclusion is directional: branded revenue declined after generic competition and loss of exclusivity, while generic volume continues to be supported by chronic heart-failure and hypertension treatment.
What is carvedilol phosphate and how does it differ from carvedilol?
Carvedilol phosphate is the extended-release salt form of carvedilol. Coreg CR uses a once-daily controlled-release capsule, while conventional carvedilol products use carvedilol, generally administered twice daily.
| Attribute |
Carvedilol phosphate ER |
Carvedilol immediate release |
| Principal U.S. brand |
Coreg CR |
Coreg |
| Dosage form |
Extended-release capsule |
Immediate-release tablet |
| Typical administration |
Once daily |
Twice daily |
| Therapeutic class |
Nonselective beta-blocker with alpha-1 blockade |
Same |
| Main uses |
Heart failure, hypertension, left-ventricular dysfunction after myocardial infarction |
Same |
| Regulatory category |
Small-molecule drug |
Small-molecule drug |
| Biosimilar exposure |
None |
None |
| Commercial status |
Mature branded and generic market |
Broad generic market |
Carvedilol reduces sympathetic stimulation and produces vasodilation through alpha-1 adrenergic blockade. The FDA-approved Coreg CR indications include mild-to-severe chronic heart failure, left-ventricular dysfunction after myocardial infarction, and hypertension.[1]
The phosphate formulation was developed to improve dosing convenience rather than to create a new pharmacologic mechanism. That distinction limits long-term pricing power. Once-daily administration can support adherence, but payers and prescribers often treat adherence benefits as insufficient to justify a large premium over twice-daily generic carvedilol.
When did Coreg CR receive FDA approval and lose exclusivity?
Coreg CR received FDA approval in 2006 under NDA 021915.[1] The product launched after the immediate-release Coreg franchise had already established carvedilol as a major heart-failure therapy.
The key commercial protection came from formulation patents and FDA regulatory exclusivity rather than new chemical entity protection. The principal patent historically associated with Coreg CR was U.S. Patent No. 6,893,662, covering controlled-release carvedilol formulations. Public Orange Book and court records identify the patent as the central asset in generic litigation involving Coreg CR.[2,3]
| Milestone |
Approximate timing |
Commercial effect |
| Coreg immediate-release approval |
1990s |
Established carvedilol franchise |
| Coreg CR approval |
2006 |
Added once-daily formulation |
| Coreg CR commercial launch |
2007 |
Extended lifecycle of carvedilol |
| Major Paragraph IV litigation |
2010s |
Delayed or contested generic entry |
| Principal formulation patent expiration |
2023 |
Removed the primary U.S. patent barrier |
| Post-expiration market |
2023 onward |
Generic pricing pressure and share erosion |
Patent expiration dates can differ by patent-term adjustment, pediatric exclusivity, disclaimer, or Orange Book listing changes. The commercial protection associated with the principal Coreg CR formulation patent ended in the 2023 period, after which generic entry became substantially more feasible.[2,3]
What patents protect carvedilol phosphate?
The Coreg CR patent estate centered on controlled-release delivery rather than the carvedilol active ingredient itself.
U.S. Patent No. 6,893,662
U.S. Patent No. 6,893,662 was directed to controlled-release carvedilol dosage forms. Its strategic value came from protecting the extended-release product architecture, including the release profile needed for once-daily administration.[2]
The patent was more commercially important than a conventional tablet formulation patent because an ANDA applicant seeking an AB-rated substitute for Coreg CR had to address the controlled-release design and demonstrate bioequivalence to the reference product.
Formulation and method-of-use protection
The Coreg CR estate should be separated into three categories:
- Active-ingredient protection, which was no longer commercially relevant because carvedilol had long been off patent.
- Formulation protection, which covered controlled release and was the principal barrier to extended-release generic entry.
- Method-of-use protection, which covered treatment indications such as heart failure or hypertension but generally provided weaker commercial protection when the same active ingredient was already widely available in immediate-release form.
Method-of-use patents can support litigation against an ANDA applicant, but their value depends on claim scope, prescribing behavior, labeling, and the ability to enforce against induced infringement. For carvedilol phosphate, formulation protection had greater practical importance than broad disease-treatment claims.
Which companies challenged Coreg CR patents?
Generic drug companies challenged Coreg CR through the abbreviated new drug application and Paragraph IV process. Public litigation records identify disputes involving GSK and multiple generic applicants, including Teva, Mylan, Sandoz, Actavis-related entities, and other ANDA sponsors.[3,4]
The litigation strategy followed the standard pattern for a branded extended-release product:
- The generic applicant filed an ANDA referencing Coreg CR.
- A Paragraph IV certification asserted that the listed patent was invalid, unenforceable, or not infringed.
- GSK filed patent-infringement litigation within the statutory period.
- FDA approval was generally stayed for up to 30 months unless the litigation was resolved earlier.
- The commercial outcome depended on claim construction, validity, settlement terms, and the timing of patent expiration.
The principal risk to GSK was not loss of carvedilol demand. Generic immediate-release carvedilol had already established the molecule as a low-cost therapy. The risk was conversion of Coreg CR prescriptions to a generic extended-release product and accelerated substitution at the pharmacy level.
What is the Orange Book status of carvedilol phosphate?
The FDA Orange Book is the controlling source for current listed patents, exclusivity, therapeutic-equivalence codes, and approved reference products.[2] Coreg CR is the reference product for carvedilol phosphate extended-release capsules.
The relevant regulatory distinction is between:
- Coreg CR, the branded reference listed drug;
- ANDA products approved as generic carvedilol phosphate extended-release capsules; and
- Immediate-release carvedilol tablets, which are not direct pharmaceutical equivalents to the extended-release capsule.
An AB-rated generic carvedilol phosphate ER product can be substituted for Coreg CR under applicable state pharmacy law. Immediate-release carvedilol cannot be substituted as a pharmaceutical equivalent because its dosage form, release characteristics, and dosing schedule differ.
FDA approval of an extended-release generic requires more than matching the active ingredient. The applicant must demonstrate pharmaceutical equivalence and bioequivalence, including an appropriate release profile. Extended-release products can face additional technical barriers involving food effects, dose dumping, pharmacokinetic variability, and manufacturing consistency.
How strong is the carvedilol phosphate patent estate?
The estate is commercially weak after principal patent expiry but was technically meaningful before generic entry.
| Factor |
Assessment |
Reason |
| Active ingredient protection |
Weak |
Carvedilol has been generic for many years |
| Extended-release formulation |
Historically strong |
Once-daily delivery created a distinct product target |
| Method-of-use claims |
Moderate to weak |
Indications overlap with generic carvedilol |
| Manufacturing know-how |
Moderate |
Release control and batch consistency can be difficult |
| Regulatory complexity |
Moderate |
ER bioequivalence and dissolution testing increase development burden |
| Post-expiry pricing power |
Low |
Multiple beta-blocker alternatives and payer pressure |
| Biosimilar barrier |
Not applicable |
Carvedilol is a small molecule |
The remaining practical barriers are development cost, manufacturing reproducibility, regulatory review, and market scale. They are not equivalent to patent exclusivity. Once a generic sponsor overcomes those barriers, the product faces immediate competition from a mature cardiovascular market.
How has carvedilol phosphate affected GSK revenue?
Coreg was a major GSK cardiovascular product before generic erosion, but Coreg CR did not create a durable standalone revenue stream comparable with a protected new chemical entity. GSK’s public reporting generally grouped Coreg sales within broader product disclosures, preventing a precise carvedilol phosphate revenue series.[5]
The financial trajectory had four stages.
1. Franchise expansion
GSK used Coreg CR to extend the carvedilol franchise after the immediate-release product had gained broad adoption. Once-daily dosing created a premium positioning opportunity and supported continued branded prescribing.
2. Lifecycle management
The extended-release product helped preserve branded value by offering convenience and a differentiated dosage form. This strategy is common for mature molecules, but its success depends on payer willingness to reimburse the formulation premium.
3. Generic substitution
Generic immediate-release carvedilol created a low-cost alternative even before extended-release competition. That limited the addressable premium market for Coreg CR. Physicians could achieve the same active-ingredient therapy with generic tablets, although dosing frequency differed.
4. Patent expiry and market normalization
After the principal formulation patent expired, generic extended-release competition reduced the remaining branded opportunity. The market shifted from a protected formulation franchise to a price-driven multisource market.
No public evidence supports treating carvedilol phosphate as a current material revenue driver for GSK. The product is better analyzed as a mature, low-growth cardiovascular asset with declining branded contribution and continuing generic demand.
What generic entry risks exist for carvedilol phosphate?
The principal generic-entry risks are substitution, price compression, and formulary exclusion.
Substitution risk
If an AB-rated generic becomes widely available, pharmacies and payers can substitute it for Coreg CR. This removes much of the brand’s remaining commercial protection.
Price risk
Extended-release carvedilol has a larger formulation-development burden than immediate-release carvedilol, but the product still contains a well-established active ingredient. Generic competition usually shifts value from product differentiation to manufacturing scale and contract pricing.
Formulary risk
Health plans may place generic carvedilol phosphate ER on preferred tiers while requiring prior authorization or higher copayments for Coreg CR. The brand can retain a niche among patients stabilized on the branded product, but that niche generally contracts over time.
Supply risk
A small number of approved manufacturers can create temporary shortages or price volatility. That risk can support short-term generic margins, but it does not restore durable branded exclusivity.
How does carvedilol phosphate compare with competing beta-blockers?
| Product |
Release profile |
Generic maturity |
Competitive position |
| Carvedilol phosphate ER |
Once daily |
Mature or emerging generic ER market |
Convenience and heart-failure familiarity |
| Carvedilol IR |
Twice daily |
Highly mature |
Lowest-cost carvedilol option |
| Metoprolol succinate ER |
Once daily |
Mature |
Strong heart-failure and hypertension competitor |
| Metoprolol tartrate |
Immediate release |
Highly mature |
Low-cost alternative |
| Bisoprolol |
Usually once daily |
Generic |
Selective beta-blocker option |
| Nebivolol |
Once daily |
Generic |
Hypertension-focused differentiation |
Carvedilol has a specific position in heart-failure treatment because it combines beta blockade with alpha-1 vasodilation. Metoprolol succinate ER is the closest commercial competitor in once-daily heart-failure therapy. The choice depends on clinical profile, tolerability, blood-pressure effects, physician preference, and payer economics.
Carvedilol phosphate therefore competes on convenience within a class where the active ingredient and therapeutic alternatives are already heavily commoditized.
Are there biosimilar risks for carvedilol phosphate?
No. Carvedilol phosphate is a chemically synthesized small molecule, not a biologic. Biosimilar approval under the Public Health Service Act does not apply. Competitive products enter through the ANDA pathway as generic drugs, subject to pharmaceutical-equivalence and bioequivalence requirements.[6]
The relevant risk is generic substitution, not biosimilar erosion.
What licensing deals and manufacturing barriers affect the product?
Public disclosures do not identify a major current licensing transaction that materially changes the carvedilol phosphate market. The commercial rights have historically been associated with GSK’s Coreg franchise, while generic products are developed and marketed by ANDA sponsors or their partners.
Manufacturing barriers remain relevant in four areas:
- Controlled-release polymer or multiparticulate design.
- Dissolution performance across the product shelf life.
- Food-effect and dose-dumping control.
- Scale-up consistency and cost-efficient capsule production.
These barriers can delay entry or limit the number of effective suppliers. They do not create durable exclusivity after the formulation patent estate has expired.
What is the likely financial trajectory for carvedilol phosphate?
The most probable trajectory is continued unit demand with declining branded value and low-to-moderate generic revenue distributed across several suppliers.
| Period |
Market condition |
Financial implication |
| Before 2006 |
Immediate-release carvedilol franchise |
High branded value |
| 2006-2012 |
Coreg CR lifecycle expansion |
Premium formulation revenue |
| 2013-2022 |
Patent litigation and controlled generic threat |
Eroding brand economics |
| 2023 onward |
Principal formulation protection expires |
Generic price compression |
| Long term |
Mature chronic-use market |
Stable volume, limited pricing power |
Revenue should be modeled from prescription volume, net price, generic count, payer mix, and supply concentration. A simple branded-growth assumption is not appropriate. The commercial opportunity is more likely to reside in manufacturing efficiency, reliable supply, and competitive contracting than in formulation-based pricing.
Key Takeaways
- Carvedilol phosphate is the active ingredient in Coreg CR, a once-daily extended-release carvedilol product.
- Its commercial differentiation is dosing convenience, not a new mechanism or new chemical entity.
- U.S. Patent No. 6,893,662 was the principal formulation patent associated with Coreg CR and expired in the 2023 period.
- Generic entry risk is high because immediate-release carvedilol and competing beta-blockers are already widely available.
- The product has no biosimilar exposure because it is a small-molecule drug.
- GSK does not publicly disclose standalone carvedilol phosphate revenue.
- Long-term value is concentrated in generic supply, manufacturing scale, and regulatory execution rather than branded pricing power.
- The closest competitive product is metoprolol succinate ER, while immediate-release carvedilol remains the main low-cost substitution risk.
FAQs About Carvedilol Phosphate Market Economics
Does carvedilol phosphate have new chemical entity exclusivity?
No. Coreg CR was an extended-release formulation of the established carvedilol molecule. Its commercial protection depended primarily on formulation patents and regulatory protections associated with the product.
Can immediate-release carvedilol replace carvedilol phosphate ER?
It can be clinically substituted only under a physician-directed regimen change. It is not an automatic pharmaceutical-equivalent substitution because the dosage form and release profile differ.
Is Coreg CR still commercially important to GSK?
Public financial reports do not establish a separately material current revenue contribution for Coreg CR. The product is best categorized as a mature legacy cardiovascular asset.
What is the biggest technical barrier to generic carvedilol phosphate?
The main barrier is demonstrating consistent extended-release performance and bioequivalence, including dissolution behavior, pharmacokinetics, food effects, and manufacturing control.
Does carvedilol phosphate have meaningful international patent protection?
Patent protection varies by jurisdiction and historical filing strategy. U.S. formulation protection has expired, while foreign markets depend on local patent status, regulatory exclusivity, and national substitution rules.
References
- U.S. Food and Drug Administration. (2006). Coreg CR (carvedilol phosphate) extended-release capsules: Prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (1999). U.S. Patent No. 6,893,662: Controlled release carvedilol formulation.
- U.S. District Court for the District of Delaware. (2010s). GlaxoSmithKline LLC v. various abbreviated new drug application sponsors.
- GSK plc. (2006-2023). Annual reports and financial results.
- U.S. Food and Drug Administration. (n.d.). Generic drugs and abbreviated new drug application guidance.
